IP Library › Granted Patent US 12,227,810
Granted Patent B2
US 12,227,810 · App. 18/430,156 · Granted Feb 18, 2025

Methods and compositions for detecting esophageal neoplasias and/or metaplasias in the esophagus

Inventors: Sanford D. Markowitz (Pepper Pike, OH); Helen Moinova (Beachwood, OH); Amitabh Chak (University Heights, OH); Joseph Willis (Shaker Heights, OH); Thomas LaFramboise (Shaker Heights, OH)
Assignee: Case Western Reserve University
C12Q1/6886C12Q1/6827C12Q1/6853G01N33/574C12Q2600/154C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,810
App. No.
18/430,156
Granted
Feb 18, 2025
Kind
B2
Abstract

The disclosure provides methods for identifying genomic loci (e.g., vimentin and/or SqBE18) that are differentially methylated in metaplasias (e.g., Barrett's esophagus) and/or neoplastic cancers (e.g., esophageal cancers). Identification of methylated genomic loci has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal metaplasias and/or neoplasias.

Claims (20)

1. A method for classifying an esophageal sample from a human subject as a methylated sample, comprising:

providing an esophageal sample obtained from the subject and treating with bisulfite to generate a plurality of bisulfite converted SqBE18 nucleic acid sequences;

amplifying the plurality of bisulfite converted SqBE18 nucleic acid sequences to generate amplicons for each bisulfite converted SqBE18 nucleic acid, wherein each amplicon is a read and wherein the amplicon comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NOs: 8318, 8360, 8332, and/or 8374, or a fragment thereof, said fragment comprising at least 50 nucleotides in length;

measuring the number of methylated cytosines of the CpG dinucleotides in each amplicon of the bisulfite converted SqBE18 nucleic acid sequence, wherein a read is classified as a methylated read when at least 70% of the cytosines in the CpG dinucleotides of the individual amplicon of the bisulfite converted SqBE18 nucleic acid sequence are methylated; and,

calculating a percentage of total reads that are methylated reads from the amplifying and measuring steps wherein the esophageal sample obtained from the human subject has at least 0.1% of the total reads that are methylated reads, whereby the esophageal sample obtained from the subject is classified as a methylated sample.

2. The method of claim 1 , further comprising sequencing each of the amplicons.

3. The method of claim 1 , wherein the amplified portion comprises 21 dinucleotides that correspond to or are derived from 21 CpG dinucleotides present in the native non-bisulfite converted SqBE18 genomic sequence.

4. The method of claim 1 , wherein the amplified portion comprises the nucleotide sequence of SEQ ID NOs: 8318, 8360, 8332 and/or 8374.

5. The method of claim 1 , wherein the esophageal sample obtained from the subject is classified as a methylated sample when 1% to 3.5% of the reads are classified as methylated reads.

6. The method of claim 4 , wherein the esophageal sample obtained from the subject is classified as a methylated sample when 1% to 3.11% of the reads are classified as methylated reads.

7. The method of claim 1 , wherein the esophageal sample obtained from the subject is classified as a methylated sample when at least 0.5% of the reads are classified as methylated reads.

8. The method of claim 1 , wherein the esophageal sample obtained from the subject is classified as a methylated sample when at least 0.76% of the reads are classified as methylated reads.

9. The method of claim 1 , wherein the amplicon comprises a nucleotide sequence that is at least 95% identical to the nucleotide sequence of SEQ ID NOs: 8318, 8360, 8332 and/or 8374.

10. The method of claim 1 , further comprising obtaining the esophageal sample by cytology brushing.

11. The method of claim 1 , further comprising obtaining the esophageal sample by balloon.

12. The method of claim 1 , wherein the amplifying is performed using PCR.

13. The method of claim 1 , wherein the amplifying comprises use of methylation-specific primers.

14. The method of claim 1 , wherein the amplifying comprises use of methylation indifferent PCR primers.

15. The method of claim 14 , wherein the amplifying comprises use of primers that are both methylation indifferent and bisulfite specific.

16. The method of claim 1 , wherein the measuring the number of methylated cytosines of the CpG dinucleotides in each amplicon is performed using sequencing wherein each cytosine base in an original template is counted as methylated or unmethylated.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2024
From: MARKOWITZ, SANFORD D.; MOINOVA, HELEN; CHAK, AMITABH; WILLIS, JOSEPH; LAFRAMBOISE, THOMAS
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 067903/0849 →
Continuity (4)
Continuation 17590986 · Feb 2, 2022
Continuation 16315405
Provisional Application 62358701 · Jul 6, 2016
Related Publication 20240191306A1 · Jun 13, 2024
References Cited (95)
US 7485420B2 · Markowitz · 2009 [cited by applicant]
US 7964353B2 · Markowitz · 2011 [cited by applicant]
US 8221977B2 · Markowitz · 2012 [cited by applicant]
US 8415100B2 · Markowitz et al. · 2013 [cited by applicant]
US 9322065B2 · Renard et al. · 2016 [cited by applicant]
US 9580754B2 · Markowitz et al. · 2017 [cited by applicant]
US 10400286B2 · Markowitz · 2019 [cited by applicant]
US 10450615B2 · Markowitz et al. · 2019 [cited by applicant]
US 11136629B2 · Markowitz et al. · 2021 [cited by applicant]
US 20070161031A1 · Trinklein et al. · 2007 [cited by applicant]
US 20080220433A1 · Ahlquist et al. · 2008 [cited by applicant]
US 20100009359A1 · Markowitz · 2010 [cited by applicant]
US 20100151468A1 · Esteller et al. · 2010 [cited by applicant]
US 20120094287A1 · Markowitz et al. · 2012 [cited by applicant]
US 20140206565A1 · Sekary et al. · 2014 [cited by applicant]
US 20160317132A1 · Markowitz et al. · 2016 [cited by applicant]
US 20170369948A1 · Markowitz et al. · 2017 [cited by applicant]
US 20190136325A1 · Markowitz et al. · 2019 [cited by applicant]
EP 2626435A1 · 2013 [cited by applicant]
EP 2850210B1 · 2018 [cited by applicant]
JP 2004505612A · 2004 [cited by applicant]
JP 2008283947A · 2008 [cited by applicant]
WO WO2010118016A2 · 2010 [cited by applicant]
WO WO2012178074A1 · 2012 [cited by applicant]
WO WO2013171504A1 · 2013 [cited by applicant]
WO WO2014159652A2 · 2014 [cited by applicant]
WO WO2016109712A1 · 2016 [cited by examiner]
WO WO2018009535A1 · 2018 [cited by applicant]
Adams et al., “Promoter Methylation in Cytology Specimens as an Early Detection Marker for Esophageal Squamous Dysplasia and Early Esophageal Squamous Cell Carcinoma”, Cancer Prevention Research, vol. 1: 357-361 (2008). [cited by applicant]
Andersson, et al., “Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer,” PLoS One, vol. 10(7): e0131889 (2015). [cited by applicant]
Andersson, et al., “Size-Based Enrichment of Exfoliated Tumor Cells in Urine Increases the Sensitivity for DNA-Based Detection of Bladder Cancer,” PLOS One, vol. 9(4): e94023 (2014). [cited by applicant]
Brait, et al., “Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer,” Cancer Epidemiology, Biomarkers and Prevention, vol. 17(1): 2786-2794 (2008). [cited by applicant]
Brait, et al., “Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression,” PLoS One, vol. 8(9): e70878 (2013). [cited by applicant]
Carvalho, et al., “Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance,” Clinical Cancer Research, vol. 17(14): 4782-4789 (2011). [cited by applicant]
Carvalho, et al., “TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma,” International Journal of Cancer, vol. 125: 1985-1991 (2009). [cited by applicant]
Chujan, et al., “CCNA1 Promoter Methylation: a Potential Marker for Grading Papanicolaou Smear Cervical Squamous Intraepithelial Lesions,” Asian Pacific Journal of Cancer Prevention, vol. 15(18): 7971-7975 (2014). [cited by applicant]
Colacino, et al., “Comprehensive Analysis of DNA Methylation in Head and Neck Squamous Cell Carcinoma Indicates Differences by Survival and Clinicopathologic Characteristics,” PLoS One, vol. 8(1): e54742 (2013). [cited by applicant]
Dennis, J. et al., Aberrant Gene Methylation in the Neoplastic Progression of Barrett's Esophagus: Identification of Candidate Diagnotic Markers, Gastroenterology, vol. 140(5), Supplement 1 (Sa1092): S-222 (2011). [cited by applicant]
Galipeau, Patricia C., “Barrett's Esophagus and Esophael Adenocarcinoma Epigenetic Biomarker Discovery Using Infinium Methylation,” illumina iCommunity Newsletter: 3-4 (2008). [cited by applicant]
GenBank record having accession AF124143. Apr. 20, 1999. [cited by applicant]
Gonzalgo, et al., “Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE),” Nucleic Acids Research, vol. 25(12): 2529-2531 (1997). [cited by applicant]
Haipeng, Bai et al., “The Research Progress of Esophageal Cancel and Its Treatment,” Journal of Baotou Medical College, vol. 30(3): (3 pages) (2014). [cited by applicant]
Hall, et al., “p16 Promoter Methylation is a Potential Predictor of Malignant Transformation in Oral Epithelial Dysplasia,” Cancer Epidemiology, Biomarkers and Prevention, vol. 17(8): 2174-2179 (2008). [cited by applicant]
Heller, et al., “Genome-Wide Transcriptional Response to 5-Aza-2′-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells,” Cancer Research, vol. 68(1): 44-54 (2008). [cited by applicant]
International Search Report and Written Opinion for Application PCT/US2015/068131 dated Jun. 6, 2016, 6 pages. [cited by applicant]
International Search Report and Written Opinion for Application PCT/US2017/040708 dated Aug. 28, 2017, 8 pages. [cited by applicant]
Kato, H. & Nakajima, M., “Treatments for esophageal cancer: a review”, Gen Thorac Cardiovasc Surg., vol. 61(6): 330-335 (Sep. 4, 2013). [cited by applicant]
Kaz et al. “Unique Methylation Signatures and Molecular Subclasses of Barrett's Esophagus and Esophageal Adenocarcinoma Revealed by Methylation Array Analysis,” Gastroenterology vol. 140 (5) Suppl. 1, S818 (May 2011). [cited by applicant]
Kaz, A.M. et al., “DNA methylation profiing in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses,” Epigenetics, Landes Bioscience, US, vol. 6(12): 1403-1412… [cited by applicant]
Kaz, et al. “Differential methylation in gene bodies and promoters in barrett's esophagus and esophageal adenocarcinoma revealed by genome-wide methylation array analysis,” Gastroenterology, vol. 144 (5) Supp. 1 (May 20… [cited by applicant]
Kim, et al., “Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell,” Biochimica et Biophysica Acta, vol. 1819: 1200-1207 (2012). [cited by applicant]
Kitkumthorn, et al., “Cyclin A1 promoter hypermethylation in human papillomavirassociated cervical cancer,” BMC Cancer, vol. 6(55) 9 pages (2006). [cited by applicant]
Klajic, et al., “DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors,” Clinical Cancer … [cited by applicant]
Koss et al., Evaluation of Esophageal Cytology Using a Neural Net-Based Interative Scanning System (the PAPNET System); Am J Clin Pathol 1998; 109:549-557 (Year: 1998). [cited by applicant]
Lee et al., “Analyzing the Cancer Methylome through targeted bisulfite sequencing”, Cancer Lett., 340(2); 16 pages (2013). [cited by applicant]
Li, et al., “A network-based, integrative approach to identify genes with aberrant co-methylation in colorectal cancer,” Molecular BioSystems, vol. 10: 180-190 (2014). [cited by applicant]
Li, et al., “Sensitive digital quantification of DNA methylation in clinical samples,” Nature Biotechnology, vol. 27(9): 858-863 (2009). [cited by applicant]
Li, et al., “Supplemental files for ‘A network-based, integrative approach to identify genes with aberrant co-methylation in colorectal cancer’,” Electronic Supplementary Material (ESI) for Molecular BioSystems, 16 page… [cited by applicant]
Liang, et al., “Integrative Identification of Epstein-Barr VirAssociated Mutations and Epigenetic Alterations in Gastric Cancer,” Gastroenterology, vol. 147(6): 1350-1362 (2014). [cited by applicant]
Lim, et al., “Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy,” Gynecologic Oncology, vol. 119: 225-231 (2010). [cited by applicant]
Lin et al., “State-of the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment,” Journal of Gastroinestinal Oncology, vol. 6(1): 3-19 (2015). [cited by applicant]
Lin et al. “Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma,” Mol Cancer Res. vol. 10, pp. 208-217 (Jan. 2012). [cited by applicant]
Loh, et al., “DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach,” BMC Gastroenterology, vol. 14(55) 11 pages (2014). [cited by applicant]
Longo, et al., “Evaluation of the methylation profile of exfoliated cell samples from patients with head and neck squamous cell carcinoma,” Head and Neck, vol. 36: 631-637 (2014). [cited by applicant]
Maldonado, et al., “An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine,” … [cited by applicant]
Moinova et al, “Aberrant Vimentin Methylation is Characteristic of Upper Gastrointestinal Pathologies,” Cancer Epidemiology, Biomarkers and Prevention, vol. 21(4): 594-600 Feb. 7, 2012. [cited by applicant]
Müller, et al., “Methylation of the Cyclin A1 Promoter Correlates with Gene Silencing in Somatic Cell Lines, while Tissue-Specific Expression of Cyclin A1 Is Methylation Independent,” Molecular and Cell Biology, vol. 20… [cited by applicant]
New England Biolabs, Random Primers, p. 111, 96/97 catalog (1997). [cited by applicant]
Ongenaert, et al., “Discovery of DNA methylation markers in cervical cancer using relaxation ranking,” BMC Medical Genomics, vol. 1(57) 15 pages (2008). [cited by applicant]
Redshaw, et al., “Quantification of epigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis”, BMC Genomics, 15:1174, 14 pages (2014). [cited by applicant]
Rettori, et al., “Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients,” Carcinogenesis, vol. 34(1): 20-27 (2013). [cited by applicant]
Rettori, et al., “TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors,” Journal of Translational Medicine, vol. 11(316) 11 pages (2013). [cited by applicant]
Sartor, et al., “Genome-wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis,” Epigenetics, vol. 6(6): 777-787 (2… [cited by applicant]
“Scientists Can Make Copies of a Gene through PCR,” Scitable by Nature Education; downloaded on May 31, 2023 from https://www.nature.com/scitable/topicpage/scientists-can-make-copies-of-a-gene-6525968/ Nature Education;… [cited by applicant]
Shah, et al. “Endoscopic options for early stage esophageal cancer”, Journal of; Gastrointestinal Oncology. 2015, vol. 6(1), pp. 20-30 (2015). [cited by applicant]
Shaw et al. The Role of Pyrosequencing in Head and Neck Cancer Epigenetics Arch Otolaryngol Head Neck Surg, vol. 134, No. 3, 251-256. (Year: 2008). [cited by applicant]
Shaw, et al., “Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing,” Nucleic Acids Research, vol. 34(11): e78 (2006). [cited by applicant]
Shaw, et al., “Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing,” British Journal of Cancer, vol. 94(4): 561-568 (2006). [cited by applicant]
Starlard-Davenport, et al., “Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach,” Journal of Carcinogenesis, vol. 12(1… [cited by applicant]
Stockdale et al. “Epigenetic alterations in Barrett's esophagus and esophageal adenocarcinoma: Identification and evaluation of potential biomarkers,” Cancer Res., vol. 74, 19 Suppl, (Oct. 1, 2014). [cited by applicant]
Sun, et al., “Comparison of Promoter Hypermethylation Pattern in Salivary Rinses Collected with and without an Exfoliating Brush with Patients with HNSCC,” PLOS One, vol. 7(3): e33642 (2012). [cited by applicant]
Sun, et al., “Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer,” Clinical Cancer Research, vol. 18(4): 1082-1091 (2012). [cited by applicant]
Tan, et al., “Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas,” British Journal of Cancer, vol. 99(2):… [cited by applicant]
Tokumaru, et al., “Aberrant Promoter Hypermethylation of Cyclin A1 in Cancer”, Japanese Journal of Head and Neck Cancer, 32(4) pp. 410-416 (2006) with English Abstract. [cited by applicant]
Tokumaru, et al., “Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing,” Cancer Research, vol. 64: 5982-5987 (2004). [cited by applicant]
Weiss, et al., “Promoter Methylation of Cyclin A1 Is Associated With Human Papillomavirus 16 Induced Head and Neck Squamous Cell Carcinoma Independently of p53 Mutation,” Molecular Carcinogenesis, vol. 50: 680-688 (2011… [cited by applicant]
Wu, et al. “Aberrant gene methylation in the neoplastic progression of Barrett's; esophagus: identification of candidate diagnostic markers”, Gastroenterology, vol.; 140, p. S-222 (2011). [cited by applicant]
Xiong, et al., “COBRA: a sensitive and quantitative DNA methylation assay,” Nucleic Acids Research, vol. 25(12): 2532-2534 (1997). [cited by applicant]
Xu, E. et al., “Genome-wide methylation analysis shows similar patterns in Barrett's Esophagus and Esophageal Adenocarcinoma,” Carcinogenesis, vol. 34(12): 2750-2756 Aug. 29, 2013. [cited by applicant]
Yanatatsaneejit, et al., “Human Papillomavirus's Physical State and Cyclin A1 Promoter Methylation in Cervical Cancer,” International Journal of Gynecological Cancer, vol. 21(5): 902-906 (2011). [cited by applicant]
Yanatatsaneejit, et al., “Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma,” Oral Oncology, vol. 44: 400-406 (2008). [cited by applicant]
Yang, et al., “Gene promoter methylation patterns throughout the process of cervical carcinogenesis,” Cellular Oncology, vol. 32: 131-143 (2010). [cited by applicant]
Yang, et al., “Methylation Markers for CCNA1 and C13ORF18 Are Strongly Associated with High-Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in Cervical Scrapings,” Cancer Epidemiology, Biomarkers and Preven… [cited by applicant]
Yu, et al., “A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer,” Clinical Cancer Research, vol. 13(24): 7296-7304 (2007). [cited by applicant]
Nava et al., “Photodynamic Therapy (PDT) Using HPPH for the Treatment of Precancerous Lesions Associated with Barrett's Esophagus,” Lasers in Surgery and Medicine, vol. 43: 705-712 (2011). [cited by applicant]